Guardant Health announced on July 15, 2025, that its test was being used in the NCI's Vanguard Study, with data presented at ASCO in Chicago and FDA review initiated for IDE.

The entities involved

• Guardant Health →

  American biotechnology company

  • Scott Bessent's call for a rate cut fuels a risk-on environment for companies like agilon health.Sun 05:03
  • EVANS welcomed Guardant Health as a sponsor for a coalition planning events across North America.Sat 21:20
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• National Cancer Institute →

  public hospital in Milan dedicated to cancer care

  • PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Sun 13:48
  • NI EH S, NCI, and NTP join a joint technical working group to strengthen scientific review through HHS/EPA partnership.Thu 18:58

Related events

• A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.Sep 2
• Ondine Biomedical Inc. is seeking a pre-NDA meeting with the FDA regarding LANTERN results while conducting clinical trials in the US and Canada.Sep 10
• A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.Aug 19
• Data was presented in Athens supporting a future U.S. NDA submission to the FDA.Sep 4
• The FDA requested additional clinical data from Unicycive Therapeutics.Jun 29